There are two million individuals in serious trouble with cocaine, and with the exception of alcohol, cocaine still accounts for the largest proportion of admissions for drug treatment. Projects 1 and 2 will test potential medications in controlled outpatient trials. Project 2, on the other hand, will examine in a controlled laboratory setting, the interactive effects of potential medications in experienced cocaine users, who are not seeking treatment, given the opportunity to self-administered cocaine, providing important information about safety, potential clinical utility, and behavioral mechanism of action of potential medications. The medications were selected because of their effects of excitatory amino acids or GABA and because less information is available about them, making controlled laboratory studies essential before their use in an outpatient setting. We will evaluate in non-treatment seeking cocaine abusers, the safety and potential behavioral mechanism of action of 1) acamprosate, a partial agonist at the polyamine site of the NMDA receptor complex; 2) abecarnil, a partial agonist at the GABA-A receptor complex; 3) ACEA- 1021, an antagonist at the glycine binding site of the NMDA receptor; and 4) LY-293558, a selective antagonist at the AMPA subtype of glutamate receptor. We hypothesize that medications that reduce cocaine craving and cocaine choice in the laboratory will be effective at reducing cocaine abuse in treatment-seeking cocaine dependent individuals. We will compare the results of the clinical (Project 2) and laboratory studies (Project 3) of acamprosate and abecarnil. The extent to which the laboratory data predict the clinical data will inform us about the utility of laboratory studies to assess medications that were chosen to disrupt the long-term changes associated with cocaine dependence. The focus on excitatory amino acids and GABA systems, which exert reciprocal effects on the dopamine system, will provide a novel venue for further explorations in the search for pharmacological adjuncts for the treatment of cocaine dependence.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
5P50DA012761-04
Application #
6654086
Study Section
Special Emphasis Panel (ZDA1)
Project Start
2002-09-01
Project End
2003-08-31
Budget Start
Budget End
Support Year
4
Fiscal Year
2002
Total Cost
Indirect Cost
Name
New York State Psychiatric Institute
Department
Type
DUNS #
167204994
City
New York
State
NY
Country
United States
Zip Code
10032
Kalapatapu, Raj K; Bedi, Gillinder; Haney, Margaret et al. (2012) The subjective effects of cocaine: relationship to years of cocaine use and current age. Am J Drug Alcohol Abuse 38:530-4
Vosburg, Suzanne K; Hart, Carl L; Haney, Margaret et al. (2010) Modafinil does not serve as a reinforcer in cocaine abusers. Drug Alcohol Depend 106:233-6
Bisaga, Adam; Aharonovich, Efrat; Cheng, Wendy Y et al. (2010) A placebo-controlled trial of memantine for cocaine dependence with high-value voucher incentives during a pre-randomization lead-in period. Drug Alcohol Depend 111:97-104
Levin, Frances R; Bisaga, Adam; Raby, Wilfrid et al. (2008) Effects of major depressive disorder and attention-deficit/hyperactivity disorder on the outcome of treatment for cocaine dependence. J Subst Abuse Treat 34:80-9
Vosburg, Suzanne K; Hart, Carl L; Haney, Margaret et al. (2005) An evaluation of the reinforcing effects of memantine in cocaine-dependent humans. Drug Alcohol Depend 79:257-60